Center for Breakthrough Medicines Now Provides a Clinically Tested Adherent Manufacturing Platform for AAV Production
The Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing critical challenges associated with the commercialization of cell and gene therapies, has completed a successful technology transfer of the University of Pennsylvania Gene Therapy Program’s (GTP) adherent cell manufacturing platform for producing Adeno-Associated Virus (AAV) gene therapies. As GTP’s exclusive CDMO partner, CBM clients will have immediate access to the adherent platform for AAV vector manufacturing, enabling rapid acceleration of AAV assets from discovery to the clinic.
Comprehensive and scalable, the GTP-developed platform has been well characterized and can be used to quickly manufacture high-quality advanced AAV gene therapies. The manufacturing platform has been used to manufacture 100 successful production scale batches and production runs for four clinical phase programs. With limited process development required and materials ready to go, the manufacturing platform may enable clinical candidate selection to Tox in as little as four months and clinical candidate selection to GMP in as little as six months.
In addition, the GTP-developed platform helps to accelerate development via advanced assays and analytics, onsite testing, reduced sample requirements, and reduced testing turn-around times. The platform’s manufacturing process is applicable across multiple AAV serotypes and genes of therapeutic product development interest. Additionally, its downstream process has an average recovery of 30% and results in greater than 80% full capsids by analytical ultracentrifuge analysis and can pool up to three upstream runs into a single downstream harvest with a typical yield of 4.8E16 total GC at harvest.
“As the exclusive CDMO provider of the GTP-developed platform, CBM is able to provide its clients the option of a well-characterized adherent AAV platform to advance their programs from discovery to first-in-human studies safely and rapidly, with less risk and expense,” said Jennifer Manning, SVP of Global Strategic Partnerships at CBM. “The platform, combined with CBM’s manufacturing expertise and state-of-the-art, high throughput cGMP suites, as well as on-site experts, provides innovator companies the critical elements required to efficiently translate lifesaving therapies from bench to bedside.”
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more